Market Overview

Tekmira Up 6% On Leerink Initiation

Related TKMR
Tekmira Officially Becomes Arbutus Biopharma
5 Biotech Stocks On Deck With The FDA

Shares of Tekmira Pharmaceuticals (NASDAQ: TKMR) are up six percent in Monday’s pre-market trading following commentary by Leerink partners.

Leerink initiated coverage at Outperform and assigned a $25 price target.

Monday’s rally follows a 50 percent peak to trough selloff last week and 10 percent climb Friday.

Shares of Tekmira were last trading at $19.25, up 6.47 percent.

Latest Ratings for TKMR

Jun 2015Maxim GroupDowngradesBuyHold
Jun 2015Maxim GroupDowngradesHold
Nov 2014Stifel NicolausMaintainsBuy

View More Analyst Ratings for TKMR
View the Latest Analyst Ratings

Posted-In: LeerinkPrice Target Initiation Analyst Ratings Movers


Related Articles (TKMR)

View Comments and Join the Discussion!

Latest Ratings

TVPTImperial CapitalDowngrades15.8
ACORGoldman SachsDowngrades10.0
BCOVB. Riley FBRUpgrades12.0
CAMPFirst AnalysisDowngrades22.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Deutsche Bank Downgrades RenaissanceRe As Premium Valuation Could Be At Risk

TRI Pointe Expands With 649 New Lot Acquisitions For 7 New Communities